Chemical Nameenfortumab vedotin
Dosage FormInjection (intravenous; 20 mg/vial, 30 mg/vial)
Drug ClassNectin-4-directed antibody and microtubule inhibitor conjugate
CompanyAstellas Pharma
Approval Year2019


  • For the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
Document TitleYearSource
Padcev (enfortumab vedotin-ejfv) Prescribing Information. 2022Astellas Pharma US, Inc., Northbrook, Illinois
Document TitleYearSource
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.2021Annals of Oncology
Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology.2020Journal of the National Comprehensive Cancer Network
Treating bladder cancer.2020American Cancer Society
Drug updated on 6/26/2023

More on this drug: Clinical Trials